A similar OS benefit from ICI treatment, regardless of BRAF mutation status, was evidenced also in a sub-analysis of 11 patients with BRAF-mutant NSCLC enrolled in the Italian Expanded Access Program (EAP) for second-line nivolumab (median OS 11.2 months in the BRAF wild-type group and 10.3 months in those with BRAF mutations) [118]. Here, BRAF is linked to non-small cell lung carcinoma.